Separate names with a comma.
Can LSD break the 20-year drought in anxiety treatment? As MindMed advances its novel LSD therapy to a Phase 3 trial, the company aims to...
Not overly concerned - they have cash runway to 2027... trials end in 2026... if FDA approval happens in 2026 this will explode.
Psychedelics and the Future of Anxiety Relief [MEDIA]
Bank of New York Mellon Corp Purchases 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)...
Fireside chat at the 2024 Cantor Global Healthcare Conference with Robert Barrow, and CMO Dan Karlin...
After the Lykos debacle, what’s next for psychedelic therapies? While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic...
That's what I am thinking.
Several potential signals with the recent Employee Inducement Grants for MindMed I want to go over three areas. 1; what is the outlook for...
This study explored pharmacological and extra-pharmacological predictors of the LSD experience. While dose emerged as the most influential...
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants https://www.nature.com/articles/s41398-024-03074-9
back at pre fda announcement levels. Accumulation zone for me. Perfect entry time for the next wave up. price action will be incredible as we...
H.C. Wainwright adjusted its outlook on MindMed (NASDAQ:MNMD) stock, increasing the price target to $55 from the previous $35 while reaffirming a...
Just a little interesting note. David Gryska, Board Director, Chair of Audit Committee for MindMed increased his shares by 20% as of 8/23 See...
MindMed has Institutional Ownership of 51.01% which is the highest in all companies in this space and is 14.91% of the PSIL ETF which is the...
Wont stay at these levels for long. I suspect the same about Lycos. They are in lock step with FDA and have the right team to pull this off. Big...
Evaluating passive physiological data collection during Spravato treatment...
Acquisitions of Biotechs - A Discussion concerning the possibility of a MindMed buyout over the next year... Acquisitions of drug companies,...
Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet...
Psychedelic Stocks: Focus on the Cash Podcast Listen to this... https://open.spotify.com/episode/3nZBsome6WoTEwMhaN8B5y
MindMed Reports Second Quarter 2024 Financial Results and Business Updates...
